NCT02579811View on ClinicalTrials.gov

Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 30, 2015

Primary Completion Date

August 21, 2019

Study Completion Date

June 20, 2023

Conditions
Metastatic Renal Cell Cancer
Interventions
DRUG

Axitinib

The intent is to maximize sustained dose intensity of axitinib based on individual tolerability using dose modification criteria

Trial Locations (4)

37232

Vanderbilt-Ingram Cancer Center, Nashville

43210

The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Columbus

44195

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland

91010

City of Hope Comprehensive Cancer Center, Duarte

All Listed Sponsors
lead

Case Comprehensive Cancer Center

OTHER

NCT02579811 - Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer | Biotech Hunter | Biotech Hunter